FunPep (4881) Stock Overview
Engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
4881 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
FunPep Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥94.00 |
| 52 Week High | JP¥163.00 |
| 52 Week Low | JP¥75.00 |
| Beta | 0.76 |
| 1 Month Change | 22.08% |
| 3 Month Change | -4.08% |
| 1 Year Change | -32.86% |
| 3 Year Change | -44.05% |
| 5 Year Change | -85.74% |
| Change since IPO | -87.95% |
Recent News & Updates
Is FunPep (TSE:4881) In A Good Position To Deliver On Growth Plans?
Dec 17
We're Hopeful That FunPep (TSE:4881) Will Use Its Cash Wisely
May 20Recent updates
Shareholder Returns
| 4881 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 5.6% | 0.2% | -0.6% |
| 1Y | -32.9% | 7.5% | 31.3% |
Return vs Industry: 4881 underperformed the JP Biotechs industry which returned 5.9% over the past year.
Return vs Market: 4881 underperformed the JP Market which returned 30.9% over the past year.
Price Volatility
| 4881 volatility | |
|---|---|
| 4881 Average Weekly Movement | 5.1% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 8.0% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4881 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4881's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 15 | Toshimi Miyoshi | www.funpep.co.jp |
FunPep Company Limited engages in the research and development of pharmaceuticals drugs, functional cosmetics, and medical devices based on functional peptides. The company is developing SR-0379, a functional peptide for skin ulcer; FPP003, an antibody-inducing peptide that is in Phase II clinical study for the treatment of psoriasis in Australia, as well as phase II clinical trial for ankylosing spondylitis in Japan; and FPP004X, an antibody-inducing peptide for pollinosis. It is also developing FPP006, a corona peptide vaccine; and FPP005, a antibody including peptide for psoriasis.
FunPep Company Limited Fundamentals Summary
| 4881 fundamental statistics | |
|---|---|
| Market cap | JP¥3.81b |
| Earnings (TTM) | -JP¥1.56b |
| Revenue (TTM) | JP¥3.00m |
Is 4881 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4881 income statement (TTM) | |
|---|---|
| Revenue | JP¥3.00m |
| Cost of Revenue | JP¥0 |
| Gross Profit | JP¥3.00m |
| Other Expenses | JP¥1.57b |
| Earnings | -JP¥1.56b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 12, 2026
| Earnings per share (EPS) | -38.56 |
| Gross Margin | 100.00% |
| Net Profit Margin | -52,133.33% |
| Debt/Equity Ratio | 0% |
How did 4881 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 15:28 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FunPep Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.